Evidence map›Paper›PMID 40152114›Full record

ArticleHistology and histopathology2025

Challenging diagnosis in pulmonary nut carcinoma: A report of two cases with different histopathologic and molecular features and a novel

Ling Xie, Jie Chen, Fei Ke, YanYing Zheng, Hui Li

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ling Xie *Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jie Chen *Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Fei KeDepartment of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
YanYing ZhengDepartment of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Hui LiDepartment of Pathology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. lihui19830401@163.com.

Funding

Research Foundation of Jiangsu Provincial Commission of Health and Family Planning M2021016
6 · The paper itself

Abstract

backgroundNUT carcinoma (NC), formerly known as NUT midline carcinoma, is a rare but highly aggressive cancer. It is a poorly differentiated carcinoma characterized by rearrangements of the

methodWe report here two cases of pulmonary NC with different clinicopathological and molecular presentations to draw attention to some atypical clinicopathologic features that can help clinicians and pathologists consider this rare entity.

resultsThe first case shows a nested pattern with small, uniform, blue epithelioid cells and aberrant expression of neuroendocrine markers, which has a known

conclusionAs a result, our study contributes to expanding the variant spectrum of the

Indexed as

CarcinomaLung NeoplasmsNeoplasm ProteinsNuclear ProteinsOncogene ProteinsOncogene Proteins, FusionAgedBiomarkers, TumorDiagnosis, DifferentialFemaleGene FusionHumansMaleMiddle AgedBiomarkers, TumorNeoplasm ProteinsNuclear ProteinsNUTM1 protein, humanOncogene ProteinsOncogene Proteins, Fusion

Identifiers

PMID40152114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.